<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03138915</url>
  </required_header>
  <id_info>
    <org_study_id>81600510</org_study_id>
    <nct_id>NCT03138915</nct_id>
  </id_info>
  <brief_title>Radiomics-based Hepatic Venous Pressure Gradient (rHVPG) (CHESS1701)</brief_title>
  <acronym>rHVPG</acronym>
  <official_title>Radiomics-based Surrogate of Hepatic Venous Pressure Gradient (rHVPG) for Noninvasive Detection of Clinically Significant Portal Hypertension in Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>302 Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Shijitan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center diagnostic trial conducted at 4 high-volume liver centers
      in China designed to determine the diagnostic performance of radiomics-based hepatic venous
      pressure gradient (rHVPG) (investigational technology) by CT angiography (CTA) for
      noninvasive assessment of the clinically significant portal hypertension (CSPH) in patients
      with cirrhosis. Direct hepatic venous pressure gradient (HVPG) measurement by means of
      catheterization of a hepatic vein with a balloon catheter is the gold-standard method to
      assess the presence of CSPH, which is defined as HVPG≥10 mmHg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center diagnostic trial conducted at 4 high-volume liver centers
      (302 Hospital of PLA; Beijing Shijitan Hospital; The Third Xiangya Hospital of Central South
      University; Beijing Youan Hospital) in China designed to determine the diagnostic performance
      of radiomics-based hepatic venous pressure gradient (rHVPG) (investigational technology) by
      CT angiography (CTA) for noninvasive assessment of the clinically significant portal
      hypertension (CSPH) in patients with cirrhosis. Direct hepatic venous pressure gradient
      (HVPG) measurement by means of catheterization of a hepatic vein with a balloon catheter is
      the gold-standard method to assess the presence of CSPH, which is defined as HVPG≥10 mmHg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 18, 2017</start_date>
  <completion_date type="Actual">October 8, 2017</completion_date>
  <primary_completion_date type="Actual">October 8, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic Accuracy of rHVPG</measure>
    <time_frame>1 day</time_frame>
    <description>Diagnostic accuracy of rHVPG to determine presence or absence of a CSPH when compared to HVPG as the reference standard (HVPG≥10mmHg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic Performance of rHVPG</measure>
    <time_frame>1 day</time_frame>
    <description>Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of rHVPG when compared to HVPG as the reference standard (HVPG≥10mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rHVPG Numerical Correlation</measure>
    <time_frame>1 day</time_frame>
    <description>Correlation of the rHVPG numerical value with the HVPG numerical value</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">370</enrollment>
  <condition>Hypertension, Portal</condition>
  <arm_group>
    <arm_group_label>Single arm study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive CTA, HVPG measurement, and rHVPG per protocol. Intervention: Procedure: HVPG measurement</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HVPG measurement</intervention_name>
    <description>HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.</description>
    <arm_group_label>Single arm study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CTA</intervention_name>
    <description>Radiomic features were extracted from CTA images.</description>
    <arm_group_label>Single arm study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Patients providing written informed consent

          -  Patients with cirrhosis and scheduled to undergo clinically-indicated invasive HVPG
             measurement by means of catheterization of a hepatic vein with a balloon catheter

          -  Has undergone &gt; 64 multi-detector row CT within 14 days prior to hepatic vein
             catheterization

          -  No hepatic-portal vein interventional therapy between the CT and hepatic vein
             catheterization

        Exclusion Criteria:

          -  Prior transjugular intrahepatic portosystem stent-shunt surgery

          -  Prior devascularization operation

          -  Has received a liver transplant

          -  Patients with known anaphylactic allergy to iodinated contrast

          -  Pregnancy or unknown pregnancy status

          -  Patient requires an emergent procedure

          -  Any active, serious, life-threatening disease

          -  Inability to adhere to study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaolong Qi, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>302 Hospital of PLA</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Shijitan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Youan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2016 Feb;278(2):563-77. doi: 10.1148/radiol.2015151169. Epub 2015 Nov 18.</citation>
    <PMID>26579733</PMID>
  </reference>
  <reference>
    <citation>Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017 Jan;65(1):310-335. doi: 10.1002/hep.28906. Epub 2016 Dec 1. Erratum in: Hepatology. 2017 Jul;66(1):304.</citation>
    <PMID>27786365</PMID>
  </reference>
  <reference>
    <citation>de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022. Epub 2015 Jun 3.</citation>
    <PMID>26047908</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2017</study_first_submitted>
  <study_first_submitted_qc>May 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Xiaolong Qi</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>clinically significant portal hypertension</keyword>
  <keyword>hepatic venous pressure gradient</keyword>
  <keyword>radiomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

